Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198

1.

Preliminary Screening and In Vitro Confirmation of Orthopoxvirus Antivirals.

Grosenbach DW, Hruby DE.

Methods Mol Biol. 2019;2023:143-155. doi: 10.1007/978-1-4939-9593-6_9.

PMID:
31240676
2.

Effects of Treatment Delay on Efficacy of Tecovirimat Following Lethal Aerosol Monkeypox Virus Challenge in Cynomolgus Macaques.

Russo AT, Grosenbach DW, Brasel TL, Baker RO, Cawthon AG, Reynolds E, Bailey T, Kuehl PJ, Sugita V, Agans K, Hruby DE.

J Infect Dis. 2018 Sep 22;218(9):1490-1499. doi: 10.1093/infdis/jiy326.

3.

Oral Tecovirimat for the Treatment of Smallpox.

Grosenbach DW, Honeychurch K, Rose EA, Chinsangaram J, Frimm A, Maiti B, Lovejoy C, Meara I, Long P, Hruby DE.

N Engl J Med. 2018 Jul 5;379(1):44-53. doi: 10.1056/NEJMoa1705688.

4.

Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection.

Berhanu A, Prigge JT, Silvera PM, Honeychurch KM, Hruby DE, Grosenbach DW.

Antimicrob Agents Chemother. 2015 Jul;59(7):4296-300. doi: 10.1128/AAC.00208-15. Epub 2015 Apr 20.

5.

ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for orthopoxvirus wrapping.

Duraffour S, Lorenzo MM, Zöller G, Topalis D, Grosenbach D, Hruby DE, Andrei G, Blasco R, Meyer H, Snoeck R.

J Antimicrob Chemother. 2015 May;70(5):1367-80. doi: 10.1093/jac/dku545. Epub 2015 Jan 27.

PMID:
25630650
6.

The broad-spectrum antiviral compound ST-669 restricts chlamydial inclusion development and bacterial growth and localizes to host cell lipid droplets within treated cells.

Sandoz KM, Valiant WG, Eriksen SG, Hruby DE, Allen RD 3rd, Rockey DD.

Antimicrob Agents Chemother. 2014 Jul;58(7):3860-6. doi: 10.1128/AAC.02064-13. Epub 2014 Apr 28.

7.

Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox).

Mucker EM, Goff AJ, Shamblin JD, Grosenbach DW, Damon IK, Mehal JM, Holman RC, Carroll D, Gallardo N, Olson VA, Clemmons CJ, Hudson P, Hruby DE.

Antimicrob Agents Chemother. 2013 Dec;57(12):6246-53. doi: 10.1128/AAC.00977-13. Epub 2013 Oct 7.

8.

Lead optimization of an acylhydrazone scaffold possessing antiviral activity against Lassa virus.

Burgeson JR, Gharaibeh DN, Moore AL, Larson RA, Amberg SM, Bolken TC, Hruby DE, Dai D.

Bioorg Med Chem Lett. 2013 Nov 1;23(21):5840-3. doi: 10.1016/j.bmcl.2013.08.103. Epub 2013 Sep 5.

9.

Antiviral options for biodefense.

Byrd CM, Grosenbach DW, Hruby DE.

Curr Opin Virol. 2013 Oct;3(5):537-41. doi: 10.1016/j.coviro.2013.05.020. Epub 2013 Jun 15. Review.

PMID:
23773331
10.

Pharmacokinetics and interspecies allometric scaling of ST-246, an oral antiviral therapeutic for treatment of orthopoxvirus infection.

Amantana A, Chen Y, Tyavanagimatt SR, Jones KF, Jordan R, Chinsangaram J, Bolken TC, Leeds JM, Hruby DE.

PLoS One. 2013 Apr 18;8(4):e61514. doi: 10.1371/journal.pone.0061514. Print 2013.

11.

Novel benzoxazole inhibitor of dengue virus replication that targets the NS3 helicase.

Byrd CM, Grosenbach DW, Berhanu A, Dai D, Jones KF, Cardwell KB, Schneider C, Yang G, Tyavanagimatt S, Harver C, Wineinger KA, Page J, Stavale E, Stone MA, Fuller KP, Lovejoy C, Leeds JM, Hruby DE, Jordan R.

Antimicrob Agents Chemother. 2013 Apr;57(4):1902-12. doi: 10.1128/AAC.02251-12. Epub 2013 Feb 12.

12.

Discovery and optimization of potent broad-spectrum arenavirus inhibitors derived from benzimidazole and related heterocycles.

Burgeson JR, Moore AL, Gharaibeh DN, Larson RA, Cerruti NR, Amberg SM, Hruby DE, Dai D.

Bioorg Med Chem Lett. 2013 Feb 1;23(3):750-6. doi: 10.1016/j.bmcl.2012.11.093. Epub 2012 Dec 1.

PMID:
23265900
13.

Discovery and optimization of potent broad-spectrum arenavirus inhibitors derived from benzimidazole.

Dai D, Burgeson JR, Gharaibeh DN, Moore AL, Larson RA, Cerruti NR, Amberg SM, Bolken TC, Hruby DE.

Bioorg Med Chem Lett. 2013 Feb 1;23(3):744-9. doi: 10.1016/j.bmcl.2012.11.095. Epub 2012 Dec 1.

PMID:
23265895
14.

Increased susceptibility of Cantagalo virus to the antiviral effect of ST-246®.

Santos-Fernandes É, Beltrame CO, Byrd CM, Cardwell KB, Schnellrath LC, Medaglia ML, Hruby DE, Jordan R, Damaso CR.

Antiviral Res. 2013 Mar;97(3):301-11. doi: 10.1016/j.antiviral.2012.11.010. Epub 2012 Dec 17.

15.

Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans.

Leeds JM, Fenneteau F, Gosselin NH, Mouksassi MS, Kassir N, Marier JF, Chen Y, Grosenbach D, Frimm AE, Honeychurch KM, Chinsangaram J, Tyavanagimatt SR, Hruby DE, Jordan R.

Antimicrob Agents Chemother. 2013 Mar;57(3):1136-43. doi: 10.1128/AAC.00959-12. Epub 2012 Dec 17.

16.

A novel inhibitor of dengue virus replication that targets the capsid protein.

Byrd CM, Dai D, Grosenbach DW, Berhanu A, Jones KF, Cardwell KB, Schneider C, Wineinger KA, Page JM, Harver C, Stavale E, Tyavanagimatt S, Stone MA, Bartenschlager R, Scaturro P, Hruby DE, Jordan R.

Antimicrob Agents Chemother. 2013 Jan;57(1):15-25. doi: 10.1128/AAC.01429-12. Epub 2012 Oct 15.

17.

Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001.

Lederman ER, Davidson W, Groff HL, Smith SK, Warkentien T, Li Y, Wilkins KA, Karem KL, Akondy RS, Ahmed R, Frace M, Shieh WJ, Zaki S, Hruby DE, Painter WP, Bergman KL, Cohen JI, Damon IK.

J Infect Dis. 2012 Nov;206(9):1372-85. doi: 10.1093/infdis/jis510. Epub 2012 Aug 16.

18.

Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers.

Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, Leeds JM, Bolken TC, Jones KF, Jordan R, Marbury T, Ruckle J, Mee-Lee D, Ross E, Lichtenstein I, Pickens M, Corrado M, Clarke JM, Frimm AM, Hruby DE.

Antimicrob Agents Chemother. 2012 Sep;56(9):4900-5. doi: 10.1128/AAC.00904-12. Epub 2012 Jul 9.

19.

Screening for vaccinia virus egress inhibitors: separation of IMV, IEV, and EEV.

Byrd CM, Hruby DE.

Methods Mol Biol. 2012;890:113-21. doi: 10.1007/978-1-61779-876-4_6.

PMID:
22688763
20.

SAR analysis of a series of acylthiourea derivatives possessing broad-spectrum antiviral activity.

Burgeson JR, Moore AL, Boutilier JK, Cerruti NR, Gharaibeh DN, Lovejoy CE, Amberg SM, Hruby DE, Tyavanagimatt SR, Allen RD 3rd, Dai D.

Bioorg Med Chem Lett. 2012 Jul 1;22(13):4263-72. doi: 10.1016/j.bmcl.2012.05.035. Epub 2012 May 17.

PMID:
22664128
21.

Resistance to a novel antichlamydial compound is mediated through mutations in Chlamydia trachomatis secY.

Sandoz KM, Eriksen SG, Jeffrey BM, Suchland RJ, Putman TE, Hruby DE, Jordan R, Rockey DD.

Antimicrob Agents Chemother. 2012 Aug;56(8):4296-302. doi: 10.1128/AAC.00356-12. Epub 2012 May 29.

22.

Pharmacokinetic comparison of a single oral dose of polymorph form i versus form V capsules of the antiorthopoxvirus compound ST-246 in human volunteers.

Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, Bolken TC, Jordan R, Jones KF, Marbury T, Lichtenstein I, Pickens M, Corrado M, Landis P, Clarke JM, Frimm AM, Hruby DE.

Antimicrob Agents Chemother. 2012 Jul;56(7):3582-6. doi: 10.1128/AAC.06090-11. Epub 2012 Apr 23.

23.

Development of ST-246® for Treatment of Poxvirus Infections.

Jordan R, Leeds JM, Tyavanagimatt S, Hruby DE.

Viruses. 2010 Nov;2(11):2409-35. doi: 10.3390/v2112409. Epub 2010 Nov 3.

24.

Comparison of the safety and pharmacokinetics of ST-246® after i.v. infusion or oral administration in mice, rabbits and monkeys.

Chen Y, Amantana A, Tyavanagimatt SR, Zima D, Yan XS, Kasi G, Weeks M, Stone MA, Weimers WC, Samuel P, Tan Y, Jones KF, Lee DR, Kickner SS, Saville BM, Lauzon M, McIntyre A, Honeychurch KM, Jordan R, Hruby DE, Leeds JM.

PLoS One. 2011;6(8):e23237. doi: 10.1371/journal.pone.0023237. Epub 2011 Aug 15.

25.

Development of the small-molecule antiviral ST-246 as a smallpox therapeutic.

Grosenbach DW, Jordan R, Hruby DE.

Future Virol. 2011 May;6(5):653-671.

26.

Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with monkeypox virus.

Smith SK, Self J, Weiss S, Carroll D, Braden Z, Regnery RL, Davidson W, Jordan R, Hruby DE, Damon IK.

J Virol. 2011 Sep;85(17):9176-87. doi: 10.1128/JVI.02173-10. Epub 2011 Jun 22.

27.

Evaluation of Lassa antiviral compound ST-193 in a guinea pig model.

Cashman KA, Smith MA, Twenhafel NA, Larson RA, Jones KF, Allen RD 3rd, Dai D, Chinsangaram J, Bolken TC, Hruby DE, Amberg SM, Hensley LE, Guttieri MC.

Antiviral Res. 2011 Apr;90(1):70-9. doi: 10.1016/j.antiviral.2011.02.012. Epub 2011 Mar 1.

28.

Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice.

Berhanu A, King DS, Mosier S, Jordan R, Jones KF, Hruby DE, Grosenbach DW.

Vaccine. 2010 Dec 16;29(2):289-303. doi: 10.1016/j.vaccine.2010.10.039. Epub 2010 Oct 29.

29.

Tecovirimat for smallpox infections.

Bolken TC, Hruby DE.

Drugs Today (Barc). 2010 Feb;46(2):109-17. doi: 10.1358/dot.2010.46.2.1437244.

PMID:
20393639
30.

Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.

Jordan R, Chinsangaram J, Bolken TC, Tyavanagimatt SR, Tien D, Jones KF, Frimm A, Corrado ML, Pickens M, Landis P, Clarke J, Marbury TC, Hruby DE.

Antimicrob Agents Chemother. 2010 Jun;54(6):2560-6. doi: 10.1128/AAC.01689-09. Epub 2010 Apr 12.

31.

Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice.

Grosenbach DW, Berhanu A, King DS, Mosier S, Jones KF, Jordan RA, Bolken TC, Hruby DE.

Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):838-43. doi: 10.1073/pnas.0912134107. Epub 2009 Dec 22.

32.

ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.

Berhanu A, King DS, Mosier S, Jordan R, Jones KF, Hruby DE, Grosenbach DW.

Antimicrob Agents Chemother. 2009 Dec;53(12):4999-5009. doi: 10.1128/AAC.00678-09. Epub 2009 Sep 14.

33.

Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesis.

Chen Y, Honeychurch KM, Yang G, Byrd CM, Harver C, Hruby DE, Jordan R.

Virol J. 2009 Apr 28;6:44. doi: 10.1186/1743-422X-6-44.

34.

ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.

Jordan R, Goff A, Frimm A, Corrado ML, Hensley LE, Byrd CM, Mucker E, Shamblin J, Bolken TC, Wlazlowski C, Johnson W, Chapman J, Twenhafel N, Tyavanagimatt S, Amantana A, Chinsangaram J, Hruby DE, Huggins J.

Antimicrob Agents Chemother. 2009 May;53(5):1817-22. doi: 10.1128/AAC.01596-08. Epub 2009 Feb 17.

35.

Specific targeting of the F13L protein by ST-246 affects orthopoxvirus production differently.

Duraffour S, Vigne S, Vermeire K, Garcel A, Vanstreels E, Daelemans D, Yang G, Jordan R, Hruby DE, Crance JM, Garin D, Andrei G, Snoeck R.

Antivir Ther. 2008;13(8):977-90.

PMID:
19195323
36.

In vitro efficacy of ST246 against smallpox and monkeypox.

Smith SK, Olson VA, Karem KL, Jordan R, Hruby DE, Damon IK.

Antimicrob Agents Chemother. 2009 Mar;53(3):1007-12. doi: 10.1128/AAC.01044-08. Epub 2008 Dec 15.

37.

Identification of a broad-spectrum arenavirus entry inhibitor.

Larson RA, Dai D, Hosack VT, Tan Y, Bolken TC, Hruby DE, Amberg SM.

J Virol. 2008 Nov;82(21):10768-75. doi: 10.1128/JVI.00941-08. Epub 2008 Aug 20.

38.

Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model.

Nalca A, Hatkin JM, Garza NL, Nichols DK, Norris SW, Hruby DE, Jordan R.

Antiviral Res. 2008 Aug;79(2):121-7. doi: 10.1016/j.antiviral.2008.03.005. Epub 2008 Apr 23.

PMID:
18479761
39.

Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.

Jordan R, Tien D, Bolken TC, Jones KF, Tyavanagimatt SR, Strasser J, Frimm A, Corrado ML, Strome PG, Hruby DE.

Antimicrob Agents Chemother. 2008 May;52(5):1721-7. doi: 10.1128/AAC.01303-07. Epub 2008 Mar 3.

40.

Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures.

Duraffour S, Snoeck R, de Vos R, van Den Oord JJ, Crance JM, Garin D, Hruby DE, Jordan R, De Clercq E, Andrei G.

Antivir Ther. 2007;12(8):1205-16.

PMID:
18240860
41.

Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination.

Grosenbach DW, Jordan R, King DS, Berhanu A, Warren TK, Kirkwood-Watts DL, Tyavanagimatt S, Tan Y, Wilson RL, Jones KF, Hruby DE.

Vaccine. 2008 Feb 13;26(7):933-46. doi: 10.1016/j.vaccine.2007.11.095. Epub 2007 Dec 26.

42.

Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.

Berhanu A, Wilson RL, Kirkwood-Watts DL, King DS, Warren TK, Lund SA, Brown LL, Krupkin AK, Vandermay E, Weimers W, Honeychurch KM, Grosenbach DW, Jones KF, Hruby DE.

J Virol. 2008 Apr;82(7):3517-29. doi: 10.1128/JVI.01854-07. Epub 2008 Jan 16.

43.

Discovery of small molecule inhibitors of ubiquitin-like poxvirus proteinase I7L using homology modeling and covalent docking approaches.

Katritch V, Byrd CM, Tseitin V, Dai D, Raush E, Totrov M, Abagyan R, Jordan R, Hruby DE.

J Comput Aided Mol Des. 2007 Oct-Nov;21(10-11):549-58. Epub 2007 Oct 25.

PMID:
17960327
44.

Discovery and development of antiviral drugs for biodefense: experience of a small biotechnology company.

Bolken TC, Hruby DE.

Antiviral Res. 2008 Jan;77(1):1-5. Epub 2007 Aug 15. Review.

45.

Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.

Quenelle DC, Prichard MN, Keith KA, Hruby DE, Jordan R, Painter GR, Robertson A, Kern ER.

Antimicrob Agents Chemother. 2007 Nov;51(11):4118-24. Epub 2007 Aug 27.

47.
48.

The vaccinia virus F13L YPPL motif is required for efficient release of extracellular enveloped virus.

Honeychurch KM, Yang G, Jordan R, Hruby DE.

J Virol. 2007 Jul;81(13):7310-5. Epub 2007 May 2.

49.

Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection.

Sbrana E, Jordan R, Hruby DE, Mateo RI, Xiao SY, Siirin M, Newman PC, DA Rosa AP, Tesh RB.

Am J Trop Med Hyg. 2007 Apr;76(4):768-73.

PMID:
17426185
50.

A host cell membrane protein, golgin-97, is essential for poxvirus morphogenesis.

Alzhanova D, Hruby DE.

Virology. 2007 Jun 5;362(2):421-7. Epub 2007 Feb 5.

Supplemental Content

Loading ...
Support Center